Greece The future of Europe’s pharmaceutical industry will be shaped as much by manufacturing and industrial policy as by scientific innovation. Theodore Tryfon outlines how ELPEN is investing to strengthen healthcare resilience, expand internationally and support Greece’s emergence as a strategic pharmaceutical manufacturing hub, while reflecting on the policy choices that…
USA You cannot choose between performing and transforming. The organisations that succeed can do both As AI, shifting healthcare policy, growing pressure around affordability and access, and rapidly evolving models of commercialisation reshape the pharmaceutical industry, Deborah Glasser reflects on how Sanofi is positioning its specialty care business for the next…
Europe As the European Medicines Agency navigates the most significant expansion of its mandate in a generation, Executive Director Emer Cooke highlights how the regulator is further strengthening its role across the full lifecycle of medicines. Cooke sets out how EMA is enhancing its engagement from early developer support and clinical…
Europe For years, Europe’s pharmaceutical sector has warned about declining competitiveness. Today, according to Nathalie Moll, Director General of EFPIA, that concern has evolved into something far more urgent. As the US and China accelerate their industrial and innovation strategies, Europe finds itself at a critical crossroads where decisions around regulation,…
Europe Europe’s position as a global healthcare leader is being tested by intensifying competition from both the US and China. As CSL’s Dirk Hoheisel points out, this is not because Europe lacks scientific excellence, industrial strength, or innovative capacity, but – in his opinion – due to a fragmented system that…
Europe Against a backdrop of rising geopolitical tension, regulatory fragmentation, and mounting pressure on Europe’s healthcare systems, Prague-headquartered Zentiva is positioning itself as a distinctly European pharmaceutical player focused on long-term resilience, affordability, and supply security. CEO Steffen Saltofte reflects on the company’s transformation since its carve out from Sanofi, its…
Europe Europe stands at a critical moment as healthcare systems face growing pressure to accelerate patient access, adapt to more complex therapies, and remain competitive in a global innovation race increasingly shaped by the US and China. In this conversation, Iris Zemzoum discusses Europe’s readiness for next-generation therapies such as radioligand…
USA Dr Anthony Letai reflects on how a career spanning cancer biology, clinical oncology, and translational research is shaping his early priorities as Director of the National Cancer Institute. The conversation examines how NCI is navigating a shifting global research landscape while accelerating innovation, strengthening evidence-based decision-making, and reinforcing confidence across…
USA As rare disease science accelerates, regulators face growing pressure to adapt without compromising rigour. In this interview, Amy Comstock Rick explains how the FDA Rare Disease Innovation Hub is strengthening cross-centre coordination, evolving evidence expectations for ultra-rare conditions, and creating new spaces for dialogue between regulators, developers, and patients. The…
USA The United States sits at a turning point in allergy care, shaped by decades of legacy practice and a growing demand for disease-modifying solutions. In this conversation, Peter Halling outlines how ALK navigates structural complexity, builds local scale, and prepares its next wave of innovation across immunotherapy and anaphylaxis. The…
France Jerome Estampes, CFO and interim CEO of Guerbet France, discusses his journey from joining the company in 2019 through to his current dual role, navigating the challenges of generic competition, COVID-19 market disruption, and regulatory pricing pressure. With operations spanning contrast media and interventional imaging across global markets, he outlines…
Hong Kong Hong Kong is entering a pivotal new chapter in its healthcare and regulatory evolution. Under the leadership of Secretary for Health Professor Lo Chung-mau, the city is reshaping its position as a global bridge for medical innovation through the “1+ Mechanism,” the creation of the Centre for Medical Products Regulation,…
See our Cookie Privacy Policy Here
